EuroPDX Workshop, Weggis, Switzerland, 1-3- October

Leo Price, OcellO’s CEO, will give a presentation entitled: “Use of ex vivo/in vitro models as pre-testing platforms before in vivo ” on Tuesday, October 2 at 13:30-14:45

More information about the conference, click here

 

SLAS Advanced Human Models and HCA, Leiden, The Netherlands, 17-19 October

More information about the conference, click here

 

EORTC, Dublin, Ireland, 13-16 November

More information about the conference, click here

 

 

Past Events

Personalised Therapeutics Conference, Leiden, The Netherlands, 23 May 2018

Leo Price, OcellO’s CEO, gave a presentation entitled: “Functional testing of drugs in patient derived tumoroids”

More information about the conference, click here

 

Dechema 3D Cell Culture, Freiburg, Germany, 5-7 June 2018

Our team represented OcellO in the exhibition hall, Booth D2 and showcased OcellO’s technology.

The following has been presented:

Posters:

A 3D High-Content Screening assay as model system for polycystic kidney disease. Bange, T.H. Booij, W.H. Leonhard, K. Yan, D.J.M. Peters, L.S. Price

High content screening of intestinal organoid cultures to visualize and quantify immune responses. Madej, B. Herpers, L. Salinaro, K. Yan, L. Daszkiewicz, L.S. Price

Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development. Basten, B. Herpers, K. Yan, T. Giesemann, J. Schueler, W. Vader, L.S. Price

Oral presentation:

Image-based quantification of immunotherapies effects in 3D environment. Yan, L. Daszkiewicz, L.S. Price

 

More information about the conference, click here

 

World Preclinical Congress, Boston, 18-21 June 2018

Leo Price, OcellO’s CEO showcased OcellO’s technology.

More information about the conference, click here

SLAS Europe, Brussels, Belgium, 27-29 June 2018

K. Yan, OcellO’s Chief Informatics Officer, has given the following presentation:” Image-based quantification of immunotherapies effects in 3D environment.

More information about the conference, click here

EACR Annual Meeting, Amsterdam, The Netherlands, 30 June- 03 July 2018

Our team represented OcellO in the exhibition hall, Booth 8 and showcased OcellO’s technology.

The following posters have been presented:

3D in vitro cultures of PDX-derived tumour for anti-cancer drug selection and discovery

A 3D image-based quantification of organoid-immune cell interactions in the presence of immuno-modulators

More information about the conference, click here

 

CIMT Annual meeting, Mainz, Germany, 15-17 May 2018

The following poster has been presented:

A 3D image-based quantification of tumor-immune cell interaction in the the presence of immuno-modulators

More information about the conference, click here

AACR Annual Meeting, April 14-18 2018, Chicago, USA

The following posters have been presented:

A 3D image-based quantification of T cell-mediated killing of CRC organoids in the presence of immuno-modulators.

Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development.

Targeting the WNT-pathway in 3D-cultures of pancreatic cancer biopsies.

More information about the conferenceclick here

8th World ADC Europe, March 26-28 2018, Berlin, Germany:

Bram Herpers has been presenting a poster entitled:

In vitro PDX models for ADC testing

More information about the conferenceclick here

Tour to Leiden Bioscience Park of the Post-Event program of the BIO-EUROPE SPRING March 12-14 2018, Amsterdam, The Netherlands

More information about the conferenceclick here

More information about the Tour to Leiden Bioscience Parkclick here

ELRIG, Liverpool, UK, 3-4 Oct 2017

Bram Herpers has given a presentation entitled: “Phenotypic screening of anti-cancer agents in 3D-cultured human tissues”
More information about the conference, click here

High-Content Analysis 3D Screening conference, Boston, USA, 6-8 Nov 2017

Leo Price, OcellO’s CEO, has given a presentation entitled:

Testing cancer therapeutics in cultured human 3D tissues
More information about the conference, click here

SLAS High-Content Screening Conference 2017, Madrid, 19-20 Sept 2017

Hester Bange has given a presentation entitled:

A 3D High-Content Screening assay as new model system for polycystic kidney disease
More information about the conference, 
click here

 

FASEB: Polycystic Kidney Disease – 25-30 June, Big Skye MT

Hester Bange has presented a poster entitled:
3D High-Content Screening of compound libraries to identify new modulators of polycystic kidney disease
More information about the conference, click here

SelectBio Phenotypic Screening, Cambridge, UK, 25-26 April 2017

Leo Price, OcellO’s CEO, has given a keynote lecture at the SelectBio High content and Phenotypic Screening conference, Cambridge, UK. More information about the conference, click here

Cafe Scientifique at Bishop’s Stortford College, UK 10 April 2017

Leo Price, OcellO’s founder and CEO has given a talk on stem cells in cancer at the Cafe Scientifique at Bishop’s Stortford College, at the Venue: The Leo Price Theatre, Bishop’s Stortford College, Bishop’s Stortford. UK.
What are stem cells? The commonly held view of stem cells that they follow a one-way path of development into a terminally differentiated cell in an organ has been challenged. Skin cells, for example, can be ‘reprogrammed’ back to a ‘pluripotent’ state from which they can be redirected into nerve cells or heart muscle – at least in the petri dish.  In cancer, tumour cells with stem-like properties can evade chemotherapy and allow a tumour to regrow. Specifically targeting cancer stem cells may be a strategy to overcome this kind of drug resistance. We can also exploit the properties of cancer stem cells to grow mini-tumours in the lab and use them to develop new treatments. Similarly, by growing tumours from patient biopsies, we can try to identify the most effective existing treatments for each patient – so-called personalised therapy.   Some examples of these applications will be presented.
For those that are puzzled by the venue name, it is named after Leo Price, who was headmaster at Bishop’s Stortford School from 1932-1943. He is the great uncle of the speaker.

AACR in Washington, April 1-5 2017

Leo Price and Lidia Daszkiewicz presented the following posters:

in vitro PDX models: 3D cultured patient-derived tumors for compound evaluation. 

Preclinical evaluation of MCLA-158: A bispecifıc antibody targeting LGR5 and EGFR using patient-derived colon carcinoma organoids.

Live from AACR, a video discussion on how 3D cell cultures are changing how we look at tumors

For more information on the video discussion click here

 

ELRIG-Forum 2017 in Darmstadt, Germany, 09 March 2017

Bram Herpers has given a presentation entitled:
Drug screening and profiling in patient derived cultured tissues: towards in vitro (pre)clinical trials
More information about the conference, click here

 

ASCO-SITC in Orlando on February 23-25

Lidia Daszkiewicz has presented a poster entitled:

A 3D image-based quantification of immune cell-tumor spheroid interactions in the presence of checkpoint inhibition

More information about the conference, click here

  • 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 29- December 2 2016, Munich

    OcellO showcased its latest in vitro human tumor models at booth D6.

    More information about the conference, click here

  • EACR Goodbye Flat Biology October 2016, Berlin

OcellO has won the Poster award presenting the poster entitled:

Phenotypic screening and selection of bi-specific therapeutic antibodies targeting stem cells in a panel of patient derived colon carcinoma organoids: a drug discovery program free of flat biology.

More information about the conferenceclick here

Basel Life Science Week & MipTec 2016 September 2016, Basel

OcellO has been showcasing its latest in vitro human tumor models at booth D62 and presented its work in poster and presentation abstracts:

in vitro-in vivo translation: Phenotypic screening in PDX-derived tumor spheroids cultured in ECM in 384-well plates

A 3D image-based phenotypic screen of bi-specific antibodies targeting stem cells in a panel of patient derived colon carcinoma organoids

3D High-Content Screening of compound libraries to identify modulators of Polycystic Kidney Disease

Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.

More information about the conference, click here